Patrick Marcellin

65.6k total citations · 12 hit papers
635 papers, 38.8k citations indexed

About

Patrick Marcellin is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Patrick Marcellin has authored 635 papers receiving a total of 38.8k indexed citations (citations by other indexed papers that have themselves been cited), including 570 papers in Hepatology, 526 papers in Epidemiology and 71 papers in Rheumatology. Recurrent topics in Patrick Marcellin's work include Hepatitis C virus research (546 papers), Hepatitis B Virus Studies (411 papers) and Liver Disease Diagnosis and Treatment (387 papers). Patrick Marcellin is often cited by papers focused on Hepatitis C virus research (546 papers), Hepatitis B Virus Studies (411 papers) and Liver Disease Diagnosis and Treatment (387 papers). Patrick Marcellin collaborates with scholars based in France, United States and Germany. Patrick Marcellin's co-authors include Tarik Asselah, Nathalie Boyer, Victor de Lédinghen, Dominique Valla, Michel Beaugrand, Zachary Goodman, Stephanos J. Hadziyannis, Marianne Ziol, Claude Degott and Pierre Bédossa and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick Marcellin

616 papers receiving 37.6k citations

Hit Papers

Randomised trial of interferon α2b plus ribavirin for 48 ... 1998 2026 2007 2016 1998 2012 2011 2004 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    1998 1.9k citations Patrick Marcellin et al. profile →
  2. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    2012 1.3k citations Patrick Marcellin, Edward Gane et al. profile →
  3. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    2011 1.2k citations Patrick Marcellin, Stefan Zeuzem et al. New England Journal of Medicine profile →
  4. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C
    2004 1.1k citations Patrick Marcellin et al. profile →
  5. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
    2005 1.1k citations George Lau, Patrick Marcellin et al. New England Journal of Medicine profile →
  6. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
    2003 1.0k citations Patrick Marcellin, Seng Gee Lim et al. New England Journal of Medicine profile →
  7. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
    2004 847 citations Patrick Marcellin, George Lau et al. New England Journal of Medicine profile →
  8. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
    2003 749 citations Stephanos J. Hadziyannis, E. Jenny Heathcote et al. New England Journal of Medicine profile →
  9. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆
    2004 733 citations George Lau, Patrick Marcellin et al. profile →
  10. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
    2006 703 citations Stephanos J. Hadziyannis, E. Jenny Heathcote et al. profile →
  11. Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes
    2010 659 citations Patrick Marcellin et al. profile →
  12. Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening
    2018 384 citations Patrick Marcellin, B. Kutala Liver International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Marcellin France 99 34.3k 34.2k 4.1k 2.0k 1.4k 635 38.8k
David L. Thomas United States 72 21.0k 0.6× 21.7k 0.6× 4.2k 1.0× 1.5k 0.7× 1.2k 0.9× 292 27.3k
Mark Sulkowski United States 72 20.6k 0.6× 22.5k 0.7× 6.2k 1.5× 1.6k 0.8× 998 0.7× 411 26.9k
Eugene R. Schiff United States 78 22.5k 0.7× 22.8k 0.7× 3.2k 0.8× 1.3k 0.7× 1.3k 0.9× 372 28.9k
John G. McHutchison United States 95 33.6k 1.0× 37.2k 1.1× 4.7k 1.1× 3.7k 1.9× 2.6k 1.8× 467 43.6k
Thomas Berg Germany 73 20.4k 0.6× 20.3k 0.6× 3.2k 0.8× 1.3k 0.7× 2.1k 1.5× 726 28.1k
Mitchell L. Shiffman United States 75 27.7k 0.8× 27.9k 0.8× 2.8k 0.7× 2.4k 1.2× 2.0k 1.4× 275 34.4k
Janice K. Albrecht United States 48 21.7k 0.6× 23.6k 0.7× 2.9k 0.7× 2.5k 1.3× 1.2k 0.8× 117 26.0k
Antonio Craxı̀ Italy 73 20.5k 0.6× 20.4k 0.6× 1.9k 0.5× 1.9k 1.0× 1.4k 1.0× 519 27.1k
Ira M. Jacobson United States 64 15.7k 0.5× 17.0k 0.5× 3.0k 0.7× 1.5k 0.8× 1.0k 0.7× 338 19.9k
K. Rajender Reddy United States 88 24.9k 0.7× 28.3k 0.8× 3.9k 1.0× 1.8k 0.9× 2.4k 1.7× 586 37.2k

Countries citing papers authored by Patrick Marcellin

Since Specialization
Citations

This map shows the geographic impact of Patrick Marcellin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Marcellin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Marcellin more than expected).

Fields of papers citing papers by Patrick Marcellin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Marcellin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Marcellin. The network helps show where Patrick Marcellin may publish in the future.

Co-authorship network of co-authors of Patrick Marcellin

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Marcellin. A scholar is included among the top collaborators of Patrick Marcellin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Marcellin. Patrick Marcellin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Podlaha, Ondřej, Edward Gane, Maurizia Rossana Brunetto, et al.. (2019). Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Scientific Reports. 9(1). 10529–10529. 15 indexed citations
2.
Kutala, B., Jérémie Guedj, Tarik Asselah, et al.. (2014). Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease. Antimicrobial Agents and Chemotherapy. 59(2). 803–810. 9 indexed citations
3.
4.
Estrabaud, Emilie, Martine Lapalus, Philippe Broët, et al.. (2014). Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. Journal of Virology. 88(11). 6394–6402. 29 indexed citations
5.
Gane, Edward, Paul J. Pockros, Stefan Zeuzem, et al.. (2014). Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM ‐ SVR study. Liver International. 35(1). 79–89. 23 indexed citations
6.
Chan, Henry Lik‐Yuen, Marı́a Buti, Patrick Marcellin, et al.. (2013). 761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS. Journal of Hepatology. 58. S309–S310. 2 indexed citations
7.
Marcellin, Patrick, E.J. Heathcote, Thomas Berg, et al.. (2011). 739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES. Journal of Hepatology. 54. S296–S297. 6 indexed citations
8.
Rautou, Pierre‐Emmanuel, Dominique Cazals‐Hatem, Gérard Feldmann, et al.. (2011). Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. American Journal Of Pathology. 178(6). 2708–2715. 49 indexed citations
9.
Ray, Ahmed El, Rami Moucari, Tarik Asselah, et al.. (2010). 1058 INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C. Journal of Hepatology. 52. S409–S409. 1 indexed citations
10.
Erhardt, Andreas, Thomas Göbel, George Lau, et al.. (2009). Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H. Journal of Medical Virology. 81(10). 1716–1720. 32 indexed citations
11.
Pol, Stanislas & Patrick Marcellin. (2008). Prise en charge de l’hépatite C en 2008. Gastroentérologie Clinique et Biologique. 32(3). S71–S73. 3 indexed citations
12.
Asselah, Tarik, Ivan Bièche, Audrey Sabbagh, et al.. (2008). Gene expression and hepatitis C virus infection. Gut. 58(6). 846–858. 74 indexed citations
13.
14.
Broutin, Sophie, et al.. (2006). Anamnesis and diagnosis of hepatitis C. Journal de Pharmacie Clinique. 25(1). 49–56. 1 indexed citations
15.
Broutin, Sophie, et al.. (2006). Histoire naturelle et diagnostic de l’hépatite C. Journal de Pharmacie Clinique. 25(1). 49–56. 1 indexed citations
16.
Hadziyannis, Stephanos J., N.C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 9 indexed citations
17.
Martinot‐Peignoux, Michèle, Lorraine Comanor, Corinne Castelnau, et al.. (2003). Early virologic response (EVR) at week 8 is more predictive of sustained response (SR) to pegylated combination therapy than at week 12. Journal of Hepatology. 38. 154–155. 1 indexed citations
18.
Marshall, D., Ken Simpson, Michèle Martinot, et al.. (2000). Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy.. 3(1). 47–62. 1 indexed citations
19.
Marcellin, Patrick, Corinne Castelnau, N. Colas-Linhart, et al.. (1997). Incidence of Dysthyroidism during Interferon Therapy in Chronic Hepatitis C. Hormone Research. 48(5). 209–214. 17 indexed citations
20.
Marcellin, Patrick, M. Pouteau, & Jean‐Pierre Benhamou. (1995). Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. Journal of Hepatology. 22(3). 364–369. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David L. Thomas Breakdown of academic impact, for papers by Mark Sulkowski Breakdown of academic impact, for papers by Eugene R. Schiff Breakdown of academic impact, for papers by John G. McHutchison Breakdown of academic impact, for papers by Thomas Berg Breakdown of academic impact, for papers by Mitchell L. Shiffman Breakdown of academic impact, for papers by Janice K. Albrecht Breakdown of academic impact, for papers by Antonio Craxı̀ Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by K. Rajender Reddy
Rankless by CCL
2026